Orthosteric–allosteric dual inhibitors of PI5P4Kγ with potent antitumor activity in non-small cell lung cancer
Open Access
- 23 September 2025
- journal article
- Published by Elsevier in Journal of Advanced Research
- Vol. 84, 1105-1126
Abstract
No abstract availableKeywords
Funding Information
- Natural Science Research Project of Guizhou Province (QKH-zk [2022]030)
- Natural Science Foundation of Guizhou Province
- National Natural Science Foundation of China (82360674)
- National Natural Science Foundation of China (82574270)
- National Natural Science Foundation of China (22167010)
This publication has 42 references indexed in Scilit:
- Development of potent and selective degraders of PI5P4KγEuropean Journal of Medicinal Chemistry, 2022
- Expanding role of PI5P4Ks in cancer: A promising druggable targetFEBS Letters, 2021
- PI5P4Ks drive metabolic homeostasis through peroxisome-mitochondria interplayDevelopmental Cell, 2021
- C24‐Ceramide Drives Gallbladder Cancer Progression Through Directly Targeting Phosphatidylinositol 5‐Phosphate 4‐Kinase Type‐2 Gamma to Facilitate Mammalian Target of Rapamycin Signaling ActivationHepatology, 2020
- Structural Basis for Regulation of Phosphoinositide Kinases and Their Involvement in Human DiseaseMolecular Cell, 2018
- Phosphatidylinositol-5-Phosphate 4-Kinases Regulate Cellular Lipid Metabolism By Facilitating AutophagyMolecular Cell, 2018
- The Lipid Kinase PI5P4Kβ Is an Intracellular GTP Sensor for Metabolism and TumorigenesisMolecular Cell, 2016
- Depletion of a Putatively Druggable Class of Phosphatidylinositol Kinases Inhibits Growth of p53-Null TumorsCell, 2013
- The activity, evolution and association of phosphatidylinositol 5-phosphate 4-kinasesAdvances in Biological Regulation, 2012
- Regulation and cellular roles of phosphoinositide 5-kinasesEuropean Journal of Pharmacology, 2004